ホーム>>Signaling Pathways>> Tyrosine Kinase>> RET>>Pralsetinib (Blu667)

Pralsetinib (Blu667)

カタログ番号GC31780

プラルセチニブ (Blu667) (BLU-667) は、非常に強力な選択的 RET 阻害剤です。プラルセチニブ (Blu667) (BLU-667) は、WT RET、RET 変異体 V804L、V804M、M918T および CCDC6-RET 融合を、それぞれ 0.4、0.3、0.4、0.4、および 0.4 nM の IC50 で阻害します。

Products are for research use only. Not for human use. We do not sell to patients.

Pralsetinib (Blu667) 化学構造

Cas No.: 2097132-94-8

サイズ 価格 在庫数 個数
50mg
$692.00
在庫あり
10mM (in 1mL DMSO)
$195.00
在庫あり
2mg
$83.00
在庫あり
5mg
$166.00
在庫あり
10mg
$238.00
在庫あり
100mg
$1,082.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Pralsetinib (Blu667) is a highly potent and selective RET inhibitor with an IC50 of 0.4 nM for wild type RET kinase.

Pralsetinib (Blu667) is a RET inhibitor extracted from patent US20170121312A1, compound example 129[1]. Pralsetinib (Blu667) demonstrates more than 10-fold increased potency over approved MKIs against oncogenic RET variants and resistance mutants. Pralsetinib (Blu667) demonstrates potent activity (IC50=0.4 nM) against common oncogenic RET alterations, including RET M918T, an activating mutation found in MTC, as well as the CCDC6-RET fusion observed in PTC and NSCLC. Pralsetinib (Blu667) suppresses RET pathway signaling in a panel of RET-driven cell lines: LC2/ad (CCDC6-RET, NSCLC), MZ-CRC-1 (RET M918T, MTC), and TT (RET C634W, MTC)[2].

Pralsetinib (Blu667) potently inhibits growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). Pralsetinib (Blu667) showed potent dose dependent activity against both KIF5B-RET Ba/F3 and KIF5B-RET V804L Ba/F3 allograft tumors with doses as low as 10 mg/kg twice-daily[2].

[1]. Brumaker J, et al. Inhibitors of ret. US20170121312A1. [2]. Subbiah V, et al. Precision Targeted Therapy With BLU-667 for RET-Driven Cancers. American Association for Cancer Research. 10.1158/2159-8290.CD-18-0338.

レビュー

Review for Pralsetinib (Blu667)

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pralsetinib (Blu667)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.